Global Liver Disease Diagnostics Market

Liver Disease Diagnostics Market Summary

The Global Liver Disease Diagnostics Market Size Was Valued at USD 35.21 Billion in 2024 and is Expected to Reach USD 71.42 Billion by 2035, Growing at a CAGR of 6.64% from 2025 to 2035. The market for liver disease diagnostics is expanding as a result of the increased incidence of liver disorders such as hepatitis, NAFLD/NASH, and liver cancer worldwide, as well as contributory factors such as rising rates of obesity and alcohol use. 

Key Regional and Segment-Wise Insights

• In 2024, the North American liver disease diagnostics market held the biggest revenue share of 42.51%, dominating the global market.
• In 2024, the imaging segment held the biggest revenue share of 29.47% and dominated the global market based on diagnosis technique.
• In 2024, the NAFLD segment had the highest revenue share of 25.7% based on disease.

Global Market Forecast and Revenue Outlook

• 2024 Market Size: USD 35.21 Billion
• 2035 Projected Market Size: USD 71.42 Billion
• CAGR (2025-2035): 6.64%
• North America: Largest market in 2024

The market for liver disease diagnostics consists of various diagnostic methods, which serve detection and monitoring purposes for hepatitis and cirrhosis, along with fatty liver disease and liver cancer. Liver disease diagnostics comprise imaging procedures with liver function testing, biopsy, and molecular examination methods. The rising worldwide incidence of liver diseases because of alcohol use, obesity, viral infections, and sedentary ways of living functions as the main market driver. Market growth is accelerated by increasing public interest in early diagnosis, along with high demand for non-invasive diagnostic methods and an aging population. The growing occurrence of NAFLD and hepatitis B and C infections across developing and developed nations creates a continuous need for precise and accessible diagnostic solutions.

Technological advancements in liver disease diagnostics produce significant improvements in the diagnostic process. The medical field uses elastography together with new imaging technology and blood biomarkers to enhance diagnostic precision while reducing patient discomfort during minimally invasive procedures such as liver biopsies. The integration of artificial intelligence enables faster and more precise analysis of diagnostic imaging results. Various governments worldwide have launched funding initiatives and awareness campaigns alongside screening programs to fight against the rising incidence of liver diseases. This promotes the adoption of state-of-the-art diagnostic instruments.

Diagnosis Technique Insights

The imaging segment dominated the worldwide liver disease diagnostics market, with the biggest revenue share of 29.47% in 2024.  The extensive use of imaging methods, including ultrasonography, CT scans, MRIs, and elastography, for precise, non-invasive evaluation of liver shape and function is responsible for this dominance.  Particularly in diseases like cirrhosis, liver tumors, and fatty liver disease, imaging is essential for identifying liver abnormalities, tracking the course of the disease, and directing therapy choices.  Improvements in imaging technology, such as increased resolution and real-time processing, have improved patient outcomes and diagnostic accuracy even more.  The growing prevalence of chronic liver diseases and the growing desire for non-invasive diagnostics are fueling this market's expansion.

Over the course of the forecast period, the biopsy segment of the liver disease diagnostics market is anticipated to expand at a consistent CAGR.  Hepatic biopsy is still the gold standard for precisely determining hepatic inflammation, fibrosis, and staging of chronic liver disorders, even with the popularity of non-invasive diagnostic techniques.  It offers comprehensive histology data that imaging and blood tests by themselves are unable to fully capture.  Its continuous application in complicated or ambiguous instances when a precise diagnosis is essential for treatment planning supports this segment's growth.  The continued need for biopsy in specialized clinical settings can be attributed to improvements in safety and patient comfort brought about by advancements in biopsy techniques, such as image-guided and less invasive procedures.

Disease Insights

The NAFLD (Non-Alcoholic Fatty Liver Disease) segment held the highest market share of 25.7% and led the liver disease diagnostics during 2024. The worldwide prevalence of obesity, together with diabetes and metabolic syndrome, continues to rise because these three conditions serve as key risk factors for non-alcoholic fatty liver disease. The escalation of lifestyle-related liver diseases across established and emerging countries creates a rising demand for prompt NAFLD diagnostic approaches. Early detection of the disease proves challenging because patients show no symptoms, thus making regular screenings vital for accurate diagnosis. The leading position of NAFLD in the market results from advancements in non-invasive diagnostic tools, including imaging and blood biomarker approaches.

Over the projection period, the liver disease diagnostics market's NASH (Non-Alcoholic Steatohepatitis) segment is expected to expand at a notable CAGR. The surge in NASH diagnostics stems from increasing occurrences of type 2 diabetes, together with obesity and sedentary lifestyles, which drive NAFLD progression to NASH. The more severe type of fatty liver disease, known as NASH, leads to cirrhosis and liver failure along with hepatocellular cancer if it remains untreated. Pharmaceutical companies developing NASH-targeting drugs have increased demand for precise diagnostic methods, which now exist. Non-invasive diagnostic approaches based on imaging and biomarker testing have propelled the quick expansion of this market as they serve as alternatives to liver biopsies.

Regional Insights

North America held the greatest revenue share of 42.51% in 2024, dominating the worldwide liver disease diagnostics market.  This leadership position results from the elevated occurrence of liver diseases, including hepatitis and nonalcoholic fatty liver disease (NAFLD), which stem from lifestyle elements like obesity and alcohol consumption, and metabolic disorders. The region thrives because it hosts numerous industry leaders together with extensive diagnostic technology facilities and advanced healthcare systems. The ongoing research and development funding and favorable insurance reimbursement rules drive the adoption of new diagnostic approaches. The market growth of North America for liver disease diagnostics has been solidified through government efforts that focus on early disease detection and public education programs.

Europe Liver Disease Diagnostics Market Trends

The market for liver disease diagnostics in Europe experiences significant growth because of increasing hepatitis and liver cancer cases, together with NAFLD and NASH. The rising elderly population, together with increased understanding of early diagnosis and preventive healthcare approaches, drives the need for advanced diagnostic tools. The region benefits from its robust healthcare infrastructure, combined with governmental screening programs and rising investigations of non-invasive diagnostic methods. The development of innovative diagnostic solutions moves forward because diagnostic companies work together with research centers and public health entities. The market expansion stems from favorable regulatory frameworks and reimbursement schemes that support new diagnostic technologies. The increasing lifestyle-related liver diseases in Europe drive the continent to remain a primary expanding market for liver disease diagnostic services.

Asia Pacific Liver Disease Diagnostics Market Trends

The Asia Pacific liver disease diagnostics market is growing significantly because of enhanced healthcare facilities, along with rising patient numbers and increasing liver disease cases. Several factors, including widespread hepatitis transmission and growing obesity and diabetes rates, and lifestyle transformations, have led to elevated liver disease incidence across this region. China, India, and Japan experience rising investments in medical technology, together with diagnostic innovation. Government-supported healthcare programs and increased public knowledge about early detection methods are driving the adoption of liver disease diagnostic tools. The expanding middle class, together with expanded healthcare access throughout the region, drives market development, which establishes the Asia Pacific as a global growth leader for the upcoming years.

Key Liver Disease Diagnostics Companies:

The following are the leading companies in the liver disease diagnostics market. These companies collectively hold the largest market share and dictate industry trends.

• Abbott
• Siemens Healthcare GmbH
• F. Hoffmann-La Roche Ltd.
• Fujifilm Corporation
• Randox Laboratories Ltd.
• Boston Scientific Corporation
• Horiba Medical
• Thermo Fisher Scientific Inc.
• Laboratory Corporation of America Holdings
• Quest Diagnostics
• Others

Recent Developments

• In July 2025, LuminoDx declared that it will be attending the World Transplant Congress and showcasing its in-house liquid biopsy technology, which is intended for non-invasive liver transplant patient monitoring.  In the market for liver disease diagnostics, this development indicates a growing emphasis on cutting-edge diagnostic technologies to enhance post-transplant care and management.
• In May 2025, Roche launched the Elecsys PRO-C3 test, a biomarker assay designed to assess liver fibrosis severity rapidly, providing results within 18 minutes to support timely clinical decision-making in liver disease management.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the liver disease diagnostics market based on the below-mentioned segments: 

Global Liver Disease Diagnostics Market, By Diagnosis Technique

• Laboratory Tests
• Imaging
• Endoscopy
• Biopsy
• Others

Global Liver Disease Diagnostics Market, By Disease

• NAFLD
• NASH
• Fibrosis
• Cirrhosis
• HCC
• Others

Global Liver Disease Diagnostics Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa